Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Marketwired June 26, 2013

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

PR Newswire June 25, 2013

Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.

Business Wire June 25, 2013

Pomerantz Law Firm Has Filed a Class Action Against Vanda Pharmaceuticals, Inc. and Certain Officers -- VNDA

Globe Newswire June 25, 2013

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by Vanda Pharmaceuticals, Inc.

Business Wire June 20, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AVHI, RKUS, VIPS and VNDA

Accesswire June 20, 2013

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vanda Pharmaceuticals Inc.

PR Newswire June 19, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals, Inc. -- VNDA

PR Newswire June 19, 2013

Law Firm of Wohl & Fruchter LLP Announces Investigation of Vanda Pharmaceuticals, Inc.

Business Wire June 19, 2013

Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder

PR Newswire June 17, 2013

InvestorsGuru.com 44 Filtered Mid-Day Market Movers Recap

Investors Guru June 16, 2013

Positive Findings, Collaborations, and NDA Filings Strengthen Pipelines - Research Report on Clovis Oncology, MannKind, TESARO, Peregrine Pharmaceuticals, and Vanda Pharmaceuticals

PR Newswire June 6, 2013

Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder

PR Newswire June 5, 2013

Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

PR Newswire May 31, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARIA, GALE, IMMU and VNDA

Accesswire May 31, 2013

Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind

PR Newswire May 31, 2013

Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings

PR Newswire May 30, 2013

Free Research Reports on FCEL, TNP, VNDA and ZIOP Issued by the Paragon Report

Marketwired May 28, 2013

InvestorsGuru.com 40 Filtered Mid-Day Market Movers Recap

Investors Guru May 26, 2013

Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

PR Newswire May 23, 2013